Cirrhotic esophageal varices with portal vein thrombosis
Conditions
Interventions
Control group:Nadroparin calcium
Sponsors
Beijing You'an Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Endoscopic treatment of cirrhotic esophageal and gastric varices: (1) Patients with liver cirrhosis, no portal vein thrombosis confirmed by B-ultrasound or CT; (2) The Child-Pugh score of liver function can be A, B, or C; (3) The existence of moderate to severe esophageal and gastric varices confirmed by gastroscopy, regardless of whether there has been upper gastrointestinal bleeding in the past; (4) Voluntarily sign the informed consent form and accept endoscopic primary prevention or secondary prevention treatment; (5) Prothrombin activity >= 40%; platelet count >= 20 x 10^9/L; 2. Subjects of cirrhotic PVT anticoagulation therapy: (1) For patients with liver cirrhosis and esophageal and gastric varices, receive standardized endoscopic treatment and reach the endpoint of endoscopic treatment; (2) Follow-up every 3 months after endoscopic treatment, patients with PVT or acute symptomatic portal vein thrombosis found by abdominal B-ultrasound; (3) Child-Pugh score of liver function is grade A; (4) Voluntarily sign the informed consent form and receive low molecular weight heparin or rivaroxaban anticoagulant treatment.
Exclusion criteria
Exclusion criteria: 1. Endoscopic treatment of cirrhotic esophageal and gastric varices: (1) Patients with liver cirrhosis after splenectomy; (2) Patients with liver cirrhosis after TIPS; (3) Emergency endoscopic treatment of patients; (4) Those with contraindications for endoscopic treatment; 2. Subjects of cirrhotic PVT anticoagulation therapy: (1) Significantly abnormal coagulation function: prothrombin activity < 40%; platelet count < 20 x 10^9/L; (2) Combined with blood system diseases; (3) Combined with severe heart and cerebrovascular diseases; (4) Those who cannot follow up on time according to the doctor's advice; (5) After reaching the endpoint of endoscopic treatment, patients who need to take anti-platelet aggregation drugs and anticoagulant drugs during the follow-up process due to other diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| abdominal ultrasound;portal vein ultrasound; | — |
Secondary
| Measure | Time frame |
|---|---|
| whole blood cell analysis;coagulation function test;liver function test;other complications of portal hypertension and postoperative adverse effects; | — |
Countries
China
Contacts
Public ContactShibin Zhang
Beijing You'an Hospital, Capital Medical University
Outcome results
None listed